Triple negative breast cancers (TNBC) lacking estrogen, progesterone and HER2 receptors account for 10-20% of breast cancer and are indicative of poor prognosis. The development of effective treatment strategies therefore represents a pressing unmet clinical need. We previously identified a molecularly- 
Introduction
Triple negative breast cancer (TNBC), as defined by absence of estrogen receptor (ER) and progesterone receptor (PR) and lack of overexpression of HER2, is an aggressive subtype comprising 10-20% of breast cancer incidences (1) . TNBC patients have a shorter median survival time after relapse (~18 month) and more readily develop chemoresistant disease (2) . In contrast to advances in the treatment of ER-positive and HER2-positive tumors, TNBC remains a disease with poor prognosis and limited treatment options (3) . Molecular profiling suggests that while ~75% of TNBC tumors exhibit a basal-like phenotype (4) and commonly harbor BRCA1 and TP53 mutations (5) the subtype can nevertheless also be considered a heterogeneous entity (6) .
In addition to underlying genetic factors, epigenetics are increasingly recognized as playing an important role in the phenotypic and molecular heterogeneity of TNBC. Aberrant DNA promoter methylation and histone modification can lead to the deregulated expression of key TNBC-associated genes (7, 8) .
Deregulated epigenetics have also been functionally linked to processes critical to breast cancer tumorigenesis such as epithelial-mesenchymal transition (EMT) that is necessary for the tumor invasionmetastasis cascade and acquisition and maintenance of a cancer stem cell phenotype (9) . Epigenetic reconfiguration in cancer cells is brought about by aberrant recruitment of chromatin-modifying complexes that perform diverse activities. Important facilitators of epigenetic deregulation are the SIN3A, which has been implicated breast cancer pathogenesis (10) (11) (12) , and SIN3B multidomain adaptor proteins.
SIN3A and SIN3B, which lack intrinsic DNA binding activity, serve as molecular scaffolds that bridge interactions between chromatin regulators and sequence-specific DNA binding transcription factors. The multiprotein repressor complexes that are generated control cell proliferation and differentiation (13) (14) (15) .
Both SIN3A and SIN3B are characterized by a unique arrangement of four paired amphipathic α-helix (PAH1-PAH4) motifs (Fig. 1) . Despite sharing sequence homology, the different PAH domains mediate specific interactions with SIN3A and SIN3B, with the second PAH repeat (PAH2) reported to bind a functionally diverse group of proteins, including the Mad family of repressors, that contain a motif known as a SIN3 interaction domain (SID, Fig. 1 
) (13).
We previously reported that inhibition of SIN3A to interact with partner proteins via its PAH2 domain induced differentiation and inhibited tumorigenicity in TNBC (10) . This was achieved through the use of a peptide corresponding to the SID domain of MAD, which binds to SIN3-PAH2 and competes with PAH2 partner proteins. In this study we sought to identify small molecule inhibitor (SMI) mimetics of SID. We describe an in silico screen of small molecule drugs, leading to the identification of two members avermectin family of macrocyclic lactones, selamectin and ivermectin as clinical-candidate compounds for the treatment of TNBC.
Materials and Methods

Cell lines and reagents
The mouse metastatic mammary 4T1 tumor cell line (Cat# CRL-2539) and human MDA-MB-231 breast adenocarcinoma cell line (Cat# HTB-26) were purchased from the American Type Culture Collection (ATCC). The MDA-MB-231-Luc-D3H2LN Bioware (D3H2LN) cell line (16) was purchased from PerkinElmer (Cat# 119369). The mouse mammary tumor MMTV-Myc cell line has been previously reported (17, 18) . Cell lines were authenticated by short tandem repeat (STR) profiling in accordance with the standard ASN-0002-2011 in April 2015 (DDC Medical, Fairfield, OH). 4T1 cells were maintained in RPMI supplemented with 10% fetal bovine serum (FBS) and 1% Antibiotic-Antimycotic solution (Invitrogen). D3H2LN and MDA-MB-231 cell lines were maintained in DMEM supplemented with 10% FBS, 1% GlutaMAX (Invitrogen), 10mM HEPES, 1mM sodium pyruvate, non-essential amino acids and 1% antibiotic-antimycotic solution. MMTV-Myc cells were cultured in DMEM/F12 medium supplemented with 5% FBS, 1% GlutaMAX, 10mM HEPES, and 1% antibiotic-antimycotic solution.
Ivermectin was purchased from Sigma. Selamectin was synthesized in-house.
NMR Spectroscopy
The PAH2 domain of mouse SIN3A was expressed in Escherichia coli BL21 (DE3) cells in the pET22b vector (Novagen) as previously described (19) . Isotope-labeled protein was prepared from cells grown on a minimal medium containing 15 (20) .
In Silico Chemical Screening
Computational screening of chemical compounds was conducted using an ensemble of 20 NMR structures of the SIN3A PAH2 domain (19) . For the virtual screening, three of these structures were selected: the one whose root-mean-square derivations (RMSDs) with the rest are the smallest (i.e., the structure in the middle of the ensemble) and a pair of structures with RMSDs that were the largest among all pairs (i.e., the two extremes). The screening was performed on a collection of 2000 FDA-approved small molecule drugs (Microsource Discovery Systems). Two programs were used for virtual screening:
Autodock-4, combined with AutoDockTools to set up the target structure file (21) and eHiTS (22) . The screening and the analysis of the results were driven by the script set Full-screen and the program (23) . Docking was focused on the surface region of the PAH2 domain where the SID-containing protein binds, between the two longer helices near the end of the two shorter helices. The twenty top scoring ligands were tested for their binding to the SIN3A PAH2 domain experimentally by NMR spectroscopy.
GST-pull down assay
The experimental procedures were performed as reported (10) . Briefly, GST and GST-SIN3A PAH2 were prepared in Escherichia coli according to the standard procedures. MAD was immunoprecipitated from MDA-MB-231 cell lysates using rabbit polyclonal anti-MAD (C19) antibody (Santa Cruz Biotechnology). Following vehicle, compound or peptide treatment, bait protein (GST or GST-PAH2) and prey protein (immunoprecipitated MAD protein) were pre-incubated separately for 1 hour at 4°C and subjected to GST-pull down assay procedures. The protein was visualized by immunoblotting using mouse monoclonal anti-MAD (F-1) antibody (Santa Cruz Biotechnology). Tat-SID peptide consists the amino acid sequence 5-24 of MAD protein and HIV type I Tat arginine-rich RNA-binding motif as a leader sequence which has been mutated (RRR>GGG) to improve nuclear entry (10) .
Immunoblot analysis
Immunoblotting was performed according to standard procedures and visualized using ECL plus Western Blotting detection reagent (Life Technologies). Blots were probed with either anti-ERα antibody (Cell Signaling Technology, #8644) or E-cadherin antibody (Cell signaling technology, #3195). Anti-GAPDH antibody (Ambion, #4300) was used as a loading control.
Mammalian two-hybrid assay
Experiments were performed as previously described (10) . Cells were treated with 15 µM SID peptides or 10 µM compounds 24 hour post-transfection. pSID and pSID 2MUT , GAL4, pVP16-MAD, pGALO-SIN3B, GAL4 UAS X5-Tk-luc have been previously described (10) .
Duolink Proximity ligation assay
MDA-MB-231 cells were plated onto coverslips in 12 well plates and treated with vehicle, Tat-SID or compound. Cells were stained with monoclonal SIN3A (sc-5299) 1:100 and polyclonal MAD (sc-222)
1:1000 according to the manufacturer's instructions (Olink Bioscience) except utilizing 1% BSA in PBS as a blocking reagent and carrying out initial washes in PBS. Cells were counterstained in To-pro-3-iodide in PBS, 3x5 min washes at RT and mounted in Vectashield mounting medium (Vector Labs).
Images were collected on a Zeiss LSM700 confocal microscope and Duolink software was utilized to quantitate signals. Table S1 . 
Modified Boyden chamber invasion assay
Estrogen Receptor Reporter Luciferase assay
Luciferase reporter activities were measured using the Dual Luciferase reporter assay system (Promega) according to the manufacturer's instructions. To determine ERα transcriptional activity, cells grown in phenol-red free DMEM/F12 growth medium containing 5% charcoal-stripped FBS were pre-treated with 1 µM selamectin (or ivermectin) for 4 days. Cells were split, re-plated and co-transfected with 0.3 µg pGL3-ERE responsive reporter plasmids and 0.1 µg pRL-Tk expressing renilla luciferase (24) prior to vehicle or drug treatment in phenol-red free DMEM/F12 containing 1% charcoal-stripped FBS for 48hrs.
Firefly luciferase activity was normalized to renilla luciferase activity and demonstrated as ERα reporter activity.
Tumorsphere formation assay
Cells were pre-treated for 7 days in 2D culture in growth medium. For tumorsphere cultures, cells (10,000 cells per 6 well) were replated in ultra-low attachment plates (Corning Costar) for a further 7 days without treatment. Tumorsphere media contained DMEM/F12 supplemented with B27 growth supplement minus Vitamin A (Invitrogen), recombinant EGF (20ng/ml, Invitrogen) and 1% antibiotic-antimycotic solution (Invitrogen). Cells were counted and spherical colonies with a diameter of greater than 50 µm considered tumorspheres (25) . Other cell aggregates were excluded.
Aldehyde dehydrogenase (ALDH) assay
D3H2LN cells were cultured and treated with vehicle or drugs as described for the tumorsphere formation assay. Tumorspheres were dissociated using cell dissociation buffer (Invitrogen) and tested for ALDH activity (2x10 5 cells/sample), using the Aldefluor assay (Aldegen) according to the manufacturer's instructions. were scanned on a GeneChip Scanner 3000 7G. Array data were analyzed by Chipinspector 2.1 (Genomatix) and transcripts were considered to be significantly regulated if at least 3 significant probes mapped to them and the log2 fold change of the transcript calculated from these probes was above 1 or below -1. For all subsequent analyses, the median expression values of two independent biological replicates were used. Replicates were combined exhaustively, i.e. mean fold changes were calculated by comparing each replicate from the treatment group to each replicate from the control group. Log2 fold change values for genes were calculated as the average of the log2 fold change values of the corresponding significantly regulated transcripts and a False Discovery Rate (FDR) was set as 5%.
In vivo animal studies
Ingenuity pathway analysis (IPA) software (Qiagen) was used to identify significantly overrepresented pathways, cellular functions and upstream transcription factor analysis in the list of identified proteins.
Vehicle versus selamectin treatment expression data were imported into IPA and core analysis was performed to identify the most significantly regulated proteins and associated cellular functions.
Expression microarray analysis was performed according to Minimum Information About a Microarray
Gene Experiment (MIAME) guidelines and data have deposited on the Gene Expression Ontology (GEO) database with accession number GSE67438.
Drug sensitivity assay
MDA-MB-231 cells (500 cells per well) were plated in 384 well plates and exposed to small molecule inhibitors selamectin (0.5 µM) for five consecutive days after which cell viability in each well was estimated by the use of CellTitre Glo assay (Promega). Luminescence data were log2 transformed, plate median centered and then Z score standardized according to the library median effect and the library median absolute deviation (26) . Drug sensitization Z-score values of <-1.5 were considered as representing selamectin sensitization effects.
Statistical analyses
Statistical analyses were performed with GraphPad Prism software (version 5.0). The experiments were conducted with at least three independent experiments unless otherwise mentioned. Where shown, p values were calculated using the unpaired Student's t-test, Mann-Whitney or one-way ANOVA as indicated. 
Results
Avermectins are small molecule mimetics of SID peptide.
We previously selectively targeted the PAH2 domain of SIN3B corepressor through introduction of a 20-mer peptide fragment comprising amino acids 5-24 of MAD SID. The peptide effectively bound the PAH2 domain and prevented interactions with SID-containing partner proteins, leading to epigenetic reprogramming, re-expression of CDH1 and ESR1, and induction of differentiation in TNBC breast cancer cells (10) . To identify small molecule inhibitor (SMI) mimetics of the SID motif, we selected 20 domain structures identified by NMR (19) and performed an in silico screen against the structures of 2,000 FDA-approved drugs. This structure-guided analysis identified 14 candidate compounds ( Supplementary Fig. S1 ), which were screened using two complementary techniques to identify whether they could interfere with binding of MAD to SIN3 PAH2 ( Fig. 2A and B) . First, we used a mammalian two-hybrid assay as previously described (10) and consistent with previous data (10, 27) , co-expression of GAL4
DBD -Sin3B and VP16 AD -MAD led a 3.7-fold decrease in luciferase activity compared to coexpression of GAL4 DBD and VP16 AD empty vectors on a reporter under the control of GAL4 UAS elements ( Fig. 2A) . Treatment with Tat-SID peptide led to a 2-fold increase in luciferase activity compared to that found with GAL4 DBD -Sin3B and VP16 AD -MAD co-expression and the majority of candidate compounds were also found to increase luciferase activity, with the exception of compounds 9 and 10, which were cytotoxic.
We also used the proximity ligation assay (PLA) (28) to confirm the ability of the candidate compounds to block SIN3A PAH2-SID interactions. Consistent with the mammalian two-hybrid results, the 12 compounds tested were able to interfere with SIN3A PAH2-SID interactions ( Fig. 2B and Supplementary Fig. S2A ). Compound 14 (selamectin) is a member of the avermectin family of macrocyclic lactones (29) and another member of this group, ivermectin, has been approved by Food and Drug Administration (FDA) to treat human parasitic diseases, including scabies (30) . Selamectin and ivermectin share the same macrocyclic ring and differ only in the number of sugar moieties (31) . Based on the activity of selamectin in our SIN3A and SIN3B PAH2-SID interference assays and favorable druglike qualities of avermectins, these compounds were selected for further study. Consistent with the result from our initial focused screens, selamectin blocked interactions between SIN3A PAH2 and in vitrotranslated MAD (Fig. 2C) . Moreover, the degree of inhibition of interaction between SIN3A and MAD SID was dose-dependent ( Fig. 2D and Supplementary Fig. S2B ).
The NMR structure of SIN3A-PAH2 domain bound to MAD SID peptide (green) has previously been resolved (PDB: 1G1E) (19) (Fig. 2E , left panel) and we performed a detailed NMR titration to establish whether ivermectin interacts with PAH2 through residues critical for the PAH2-SID interaction. (Fig. 2E, right panel) . Similar to selamectin, PLA analysis revealed that ivermectin efficiently blocked PAH2-SID interactions, with treatment promoting a 7-fold reduction ( Fig. 2F and Supplementary Fig. S2B ).
Ivermectin and selamectin upregulate CDH1 and ESR1, inhibit invasion and confer tamoxifen sensitivity in TNBC
We tested the effect of selamectin and ivermectin on CDH1 and ESR1 expression in the wild-type MDA-MB-231 TNBC cell line as well as the mouse MMTV-Myc cell line (18) . We also used the MDA-MB-231-derived reporter cell line (MDA-MB-231-luc-D3H2LN), which possesses greater metastatic potential compared to parental MDA-MB-231 cells (16) . Consistent with our previous results with SID peptide (10), treatment with selamectin induced CDH1 mRNA expression by 2.5 to 12-fold in MDA-MB-231 and D3H2LN cell lines, respectively, and by 100-fold in MMTV-Myc cells (Fig. 3A) . Upregulation of cytoplasmic and membrane-associated E-cadherin protein was also observed after selamectin or ivermectin treatment in MDA-MB-231 ( Fig. 3B and 3C ). We previously demonstrated that stable expression of SID inhibited the formation of large and invasive colonies in 3D culture in Matrigel (10) and consistent with these results, both selamectin and ivermectin inhibited invasion in dose-dependent manner (Fig. 3D) . Selamectin treatment also resulted in the downregulation in MDA-MB-231 cells of the MMP9 and MT1-MMP/MMP14 genes that are associated with invasion and metastasis (32, 33) , (Fig. 3E) .
Treatment with selamectin also induced ESR1 mRNA expression by 4 to 11-fold, respectively, in MDA-MB-231 and D3H2LN cell lines, and by 1.5-fold in MMTV-Myc cells (Fig. 4A) . Ivermectin was also found to increase ESR1 expression in MDA-MB-231 and D3H2LN cell lines by 3-fold and 6-fold, respectively. Consistent with these results, selamectin treatment also increased levels of ERα protein (Fig.   4B ). Expression of progesterone receptor (PGR), a direct transcriptional target of ERα, was also increased by between 1.5-fold and 6-fold following treatment with selamectin or ivermectin (Fig. 4C) . We next investigated the impact of re-expression of ESR1 on ERα function. Co-treatment with selamectin in the presence of 17β-estradiol (E2), led to a 2-fold increase in ERα activity in a reporter assay, whereas cotreatment with ERα antagonist tamoxifen (Tam) led to a 2-fold reduction ERα activity (Fig. 4D) . Again, these results mirror those obtained with SID peptide (10) . Additionally, re-expression of ERα in response to selamectin treatment sensitized MDA-MB-231 and D3H2LN cells to the growth promoting or inhibiting effects of E2 or Tam, respectively (Fig. 4E ).
Ivermectin and selamectin target TNBC clonogenic self-renewal to inhibit growth and metastasis
In embryonic stem (ES) cells, SIN3A is a part of a complex that positively regulates NANOG and SOX2, expression of which are hallmarks of stem cell pluripotency and self-renewal (34 
NANOG and SOX2 interact with SIN3A-containing complexes to repress gene targets in ES cells (35) .
Consistent with this, treatment of D3H2LN cells with 0.5µM of selamectin or ivermectin reduced NANOG (Fig. 5A) and SOX2 (Fig. 5B) gene expression by 50 to 80%. Furthermore, clonogenic selfrenewal dependent (32, 33) tumorsphere growth by was diminished by 90-100% (Fig. 5C) (Fig. 5D ). Our in vitro results could also be recapitulated in vivo. Both in vitro pre-treatment of MMTV-Myc cells with selamectin ( Fig. 6A) and in vivo administration of the drug (Fig. 6B and C) led to a significant reduction in volume and mass of orthotopically-implanted tumors. Selamectin treated tumors were also observed to be locally less invasive
(not shown). In vivo treatment with selamectin also lead to a dramatic reduction in the number of lung metastases observed (Fig. 6D) . Lastly, the effect of selamectin on tumor cell dissemination and metastasis was examined following surgery to remove established tumors arising from implantation of 4T1 metastatic mammary tumor cells and was found to greatly reduce the number of lung metastases under these conditions (Fig. 6E-G) .
Selamectin treatment alters the expression of genes involved in clinically targetable TNBC pathways, leading to drug sensitization.
To further investigate the mechanism of action of selamectin in TNBC, we performed expression microarray analysis at 24 hours to identify genes and pathways upstream of E-cadherin and ERα.
Pathway analysis identified downregulation of important markers of epithelial to mesenchymal transition:
FGFR2-4, SMAD2, ID2, PIK3CA and WNT5A (Table 1 and Supplementary Table S2 ) (37) (38) (39) (40) . Genes involved in estrogen-dependent signaling were modulated (Table 2 and Supplementary Table S3 ) and upstream regulator analysis also identified activation of ER receptor signaling (Z score, 0.433; P = 1.36E-05) and the β-estradiol pathway (Z score, 0.577; P = 3.77E-04). Other associated pathways that were significantly negatively regulated included fibroblast growth factor (FGF), integrin-linked kinase (ILK) signaling (which plays an important role in silencing of E-cadherin (41)), growth hormone, and HGF cytokine signaling (Table 2 and Supplementary Table S3 is a key player in TNBC pathogenesis and represents a major therapeutic target, and a number of the receptor tyrosine kinases downregulated by selamectin, including IGF1-R (42) and FGF (40) , signal through PI3K via RAS (43) . The finding that selamectin also downregulates ITGB3 is also significant given the role of integrin α v β 3 in EMT, maintaining a cancer stem cell phenotype and conferring resistance to RTK inhibitors (44, 45) .
In parallel, we carried out a sensitivity screen in MDA-MB-231 cells to identify compound to which selamectin treatment conferred sensitization, using a focused library of 80 drugs that are either currently used in the treatment of cancer or are in late stage clinical development. We measured viability in cells exposed to compound alone versus compound in addition to selamectin. Drug sensitization Z scores of less than -1.5 for were considered significant and 23 compounds passed this threshold (Table 3) . Consistent with our results, and validating this approach, selamectin caused sensitization to 4-hydroxytamoxifen (4-OHT), an active metabolite of tamoxifen (Z score: -2.93 at 50 nM 4-OHT). In the context of TNBC therapy, other drugs with significant Z-scores included the FGFR inhibitor AZD4547 (Z score: -1.65), RTK inhibitor Sunitinib (Z score: -2.76), PI3K/mTOR inhibitor PF-04691502 (Z score: -2.78) and the IGF-1R inhibitor GSK1904529A (Z score: -2.18). It is notable that many of the drugs to which selamectin conferred sensitivity target genes and pathways modulated by selamectin treatment.
Discussion
In this study, we have identified the macrocyclic lactones selamectin and ivermectin as small molecule mimetics of a therapeutic peptide corresponding to the MAD SID motif. We demonstrated that the effects of these drugs on TNBC phenocopy SID peptide and that selamectin treatment as a single agent exhibits inhibitory activity against TNBC tumor growth and metastasis. Work to identify the molecular mechanisms underlying the activity of selamectin or ivermectin in TNBC is ongoing but candidate SIN3A/SIN3B-PAH2 interacting proteins include PF1 (PHF12) and TIEG1 (KLF10). PF1 recruits a complex containing two known breast cancer factors, EMSY and JARID1B (46) (47) (48) . JARID1B is a H3K4 demethylase and inhibition of this complex could explain, at least in part, the epigenetic remodeling we have observed with SID peptide treatment (10) . PF1 also interacts with SIN3B to modify chromatin downstream of transcriptional start sites and mitigate RNA polymerase II progression within transcribed loci (49), although it is unclear whether this plays a role in aberrant gene expression in TNBC. As its name implies, TIEG1 (TGFβ inducible early gene), plays a role in the TGFβ/SMAD signal transduction pathway where it drives expression and activation of SMAD2 (50, 51) . A direct link between TIEG1 and TGFβ pathway-associated EMT in TNBC remains to be established but it is notable that expression of SIN3A and SIN3B interact with numerous transcriptional factors via highly conserved domains comprising four paired amphipathic α-helices (PAH 1-4), a HDAC interaction domain (HID) , bound by many core corepressor components that mediate epigenetic modifications, and a C-terminal highly conserved region (HCR). The molecular structure PAH2 is highlighted together with the SIN3 interaction domain (α-helix SID, red). A list of SID-containing factors is also shown. Interactions between PAH2
and SID-containing factors may be disrupted using SID decoy peptides or avermectins. Shown is cell number ratio (treated/vehicle, blue) and luciferase activity relative to renilla control (red).
Cell number ratio and relative luciferase activity values were normalized to the value for untreated Error bars represent mean ± SD. P, unpaired t-test. C, D3H2LN cells were pre-treated with selamectin or ivermectin (7 days) at the indicated concentrations, replated in ultra-low attachment plates and cultured without treatment for a further 7 days. Cells were counted and spherical colonies with a diameter of greater than 50 µm considered to represent tumorspheres (▲). Other cell aggregates (indicated by white arrowheads) were excluded (SEL, P = 0.0117; IVM, P = 0.0033).
D, D3H2LN cells were pre-treated with selamectin or ivermectin (7 days) at the indicated concentrations, replated in ultra-low attachment plates and cultured without treatment for a further 7 days. Cells were collected to determine ALDH activity and results are quantified as number of ALDH+ cells (P = 0.0149).
Error bars represent mean ± SD. P, unpaired t-test. Tat 
